



Press Release

Leeds

18 Jan 2011

Tissuemed makes further progress

Pioneering adhesive surgical film manufacturer Tissuemed has announced that a key patent has now been formally granted 9 months after its original posting. The patent relates to TissuePatch2, which is considered background intellectual property and covers fundamental elements of the company's adhesive Terpolymer technology.

As Nick Woods, Tissuemed's CEO stated; *"Tissuemed has always had a policy of robustly protecting its technology and it is always gratifying to receive these notifications as they confirm the claim that what we have is a novel and unique proposition."*

Last year the company entered into an investment and distribution agreement with Medtronic - one of the largest medical technology companies in the world. The agreement gives Medtronic distribution rights to sell Tissuemed's neuro and spinal products - a range of ultra thin adhesive films, which adhere to the body's internal tissues to prevent the leakage of Cerebrospinal Fluid encountered in surgery.

Shackleton Director, David Hudson notes: *"Tissuemed markets products that address a range of other applications, and has an excellent development pipeline, that will be protected by this patent grant."*

– Ends –

For further information:

Shackleton Ventures Limited Wendy Roberts	+44 (0) 1962-842621 wendy.roberts@shackletonventures.com
Merlin (PR advisers to Shackleton) Vanessa Maydon Rachel Thomas	+44 (0) 2076 536620 07802 961 902 / vmaydon@merlipr.com 07787 504 447/ rthomas@merlinpr.com
Tissuemed Nick Woods	+44 (0)113 200 0500 info@tissuemed.com

Notes to editors

Shackleton Ventures

- Shackleton specialises in direct secondary venture and development capital investments – where Shackleton will buy a portfolio of existing investments, or an individual asset, from an investor that is seeking liquidity.
- Members of Shackleton's management team have over 50 years venture capital experience between them and over 80 years operational experience in senior roles in entrepreneurial businesses.
- The Shackleton Secondaries LP fund was formed in July 2006 and has 13 investments.
- The Shackleton Secondaries II LP fund was formed in November 2007 and has made 15 investments to date. The £25 million fund remains open to new investment opportunities.
- Shackleton's funds have acquired investments from 5 institutional vendors and from several private individuals.
- Both Shackleton Secondaries LP funds are managed by FSA-authorized Shackleton Finance Limited.
- For further information: www.shackletonventures.com

Tissuemed

- Tissuemed is a leading medical device company with a reputation for technical innovation dating back over twenty years. The company has its origins in the development of tissue-based therapeutic devices including developing the first tissue heart valve to gain regulatory approval in Europe.
- More recently Tissuemed has focused its considerable scientific expertise on the development of surgical sealants, culminating in the TissuePatch product family, unique surgical films with properties designed specifically to address the demands of surgeons needing to seal leakages of air, blood and other fluids.
- Tissuemed's scientists are uniquely qualified to explore future surgical developments of the company's proprietary polymer technology. There are many applications for an absorbable synthetic material that becomes adherent on contact with internal tissue surfaces. These include advances in our own barrier films, applying coatings to other surgically implantable materials and local internal drug delivery to name a few.
- For further information: www.tissuemed.com